Monoamine Oxidase-B Inhibitor Rasagiline Effects on Motor and Non-Motor Symptoms in Individuals with Parkinson’s Disease: A Systematic Review and Meta-Analysis
Objective: In the manuscript titled “Monoamine Oxidase-B Inhibitor Rasagiline Effects on Motor and Non-Motor Symptoms in Individuals with Parkinson’s Disease: A Systematic Review and Meta-Analysis”, the objective was to conduct a systematic review with meta-analysis to investigate the effects that Rasagiline has on motor and non-motor symptoms in individuals with PD. Introduction: Rasagiline is a second-generation monoamine oxidase-B (MAO-B) inhibitor used both as monotherapy and adjunctive therapy for Parkinson’s Disease (PD). Methods: A systematic literature search and meta-analysis were performed with randomized control trials that investigated the effects of Rasagiline on motor and non-motor symptoms in individuals with PD. The systematic search was conducted in PubMed, Cochrane, and EBSCO databases. Methodological quality was assessed using the Cochrane Grading Recommendations Assessment, Development and Evaluation approach. Results: Fourteen studies were included in our review. There were trivial to small and statistically significant improvements in motor symptoms for individuals with PD treated with Rasagiline compared to placebo. Non-motor symptoms showed no significant improvement with Rasagiline compared to placebo in five of six meta-analyses. Results were based on very low to moderate certainty of evidence. Conclusion: 1 mg/day Rasagiline significantly improved Parkinsonian motor symptoms in individuals with PD compared with placebo. For all outcomes, the 1 mg/day Rasagiline group was favored over the placebo group.
References
[1]
Ferreira, J.J., Katzenschlager, R., Bloem, B.R., et al. (2012) Summary of the Recommendations of the EFNS/MDS-ES Review on Therapeutic Management of Parkinson’s Disease. European Journal of Neurology, 20, 5-15. https://doi.org/10.1111/j.1468-1331.2012.03866.x
[2]
Kalia, L.V. and Lang, A.E. (2015) Parkinson’s Disease. The Lancet, 386, 896-912. https://doi.org/10.1016/S0140-6736(14)61393-3
[3]
Tsuboi, T., Satake, Y., Hiraga, K., et al. (2022) Effects of MAO-B Inhibitors on Non-Motor Symptoms and Quality of Life in Parkinson’s Disease: A Systematic Review. NPJ Parkinson’s Disease, 8, Article No. 75. https://doi.org/10.1038/s41531-022-00339-2
[4]
Chen, J., Swope, D. and Dashtipour, K. (2007) Comprehensive Review of Rasagiline, A Second-Generation Monoamine Oxidase Inhibitor, for the Treatment of Parkinson’s Disease. Clinical Therapeutics, 29, 1825-1849. https://doi.org/10.1016/j.clinthera.2007.09.021
[5]
Riederer, P. and Laux, G. (2011) MAO-Inhibitors in Parkinson’s Disease. Experimental Neurobiology, 20, 1-17. https://doi.org/10.5607/en.2011.20.1.1
[6]
Chang, H.Y., Li, Y.Y., Hong, C.T. and Kuan, Y.C. (2022) Efficacy of Rasagiline Monotherapy for Early Parkinson Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Psychopharmacology, 36, 704-714. https://doi.org/10.1177/02698811221093795
[7]
Stocchi, F. and Rabey, J.M. (2011) Effect of Rasagiline as Adjunct Therapy to Levodopa on Severity of off in Parkinson’s Disease. European Journal of Neurology, 18, 1373-1378. https://doi.org/10.1111/j.1468-1331.2011.03512.x
[8]
Page, M.J., McKenzie, J.E., Bossuyt, P.M., et al. (2021) The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. British Medical Journal, 372, n71.
[9]
Scanlon, B.K., Katzen, H.L., Levin, B.E., Singer, C. and Papapetropoulos, S. (2008) A Formula for the Conversion of UPDRS-III Scores to Hoehn and Yahr Stage. Parkinsonism & Related Disorders, 14, 379-380. https://doi.org/10.1016/j.parkreldis.2007.09.010
[10]
University of Oxford: Parkinson’s Disease Questionnaire. Oxford University Innovation. https://innovation.ox.ac.uk/outcome-measures/parkinsons-disease-questionnaire-pdq-39-pdq-8/
[11]
Nayak, L. and Henchcliffe, C. (2008) Rasagiline in Treatment of Parkinson’s Disease. Neuropsychiatric Disease and Treatment, 4, 23-32. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515917/#:~:text=Rasagiline prevents dopamine metabolism irreversibly
[12]
Clarke, C.E., Smitaa, P., Ives, N., et al. (2016) UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria. https://www.ncbi.nlm.nih.gov/books/NBK379754/
[13]
Sterne, J.A.C., Savović, J., Page, M.J., et al. (2019) RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials. BMJ, 366, L4898. https://doi.org/10.1136/bmj.l4898
[14]
Cohen, J. (1992) A Power Primer. Psychological Bulletin, 112, 155-159. https://doi.org/10.1037/0033-2909.112.1.155
[15]
(2019) Cochrane. 9.5.2 Identifying and Measuring Heterogeneity. https://handbook-5-1.cochrane.org/chapter_9/9_5_2_identifying_and_measuring_heterogeneity.htm
[16]
(2019) Cochrane. 10.4.3.1 Recommendations on Testing for Funnel Plot Asymmetry. https://handbook-5-1.cochrane.org/chapter_10/10_4_3_1_recommendations_on_testing_for_funnel_plot_asymmetry.htm
[17]
Zeng, L., Brignardello-Petersen, R., Hultcrantz, M., et al. (2021) GRADE Guidelines 32: GRADE Offers Guidance on Choosing Targets of GRADE Certainty of Evidence Ratings. Journal of Clinical Epidemiology, 137, 163-175. https://doi.org/10.1016/j.jclinepi.2021.03.026
[18]
Rabey, J.M., Sagi, I., Huberman, M., et al. (2000) Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson’s Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa. Clinical Neuropharmacology, 23, 324-330. https://doi.org/10.1097/00002826-200011000-00005
[19]
Stern, M.B., Marek, K.L., Friedman, J., et al. (2004) Double-Blind, Randomized, Controlled Trial of Rasagiline as Monotherapy in Early Parkinson’s Disease Patients. Movement Disorders, 19, 916-923. https://doi.org/10.1002/mds.20145
[20]
Parkinson Study Group (2005) A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations. Archives of Neurology, 62, 241-248. https://doi.org/10.1001/archneur.62.2.241
[21]
Rascol, O., Brooks, D., Melamed, E., et al. (2005) Rasagiline as an Adjunct to Levodopa in Patients with Parkinson’s Disease and Motor Fluctuations (LARGO, Lasting Effect in Adjunct Therapy with Rasagiline Given Once Daily, Study): A Randomised, Double-Blind, Parallel-Group Trial. The Lancet, 365, 947-954. https://doi.org/10.1016/S0140-6736(05)71083-7
[22]
Olanow, C.W., Rascol, O., Hauser, R., et al. (2009) A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson’s Disease. New England Journal of Medicine, 361, 1268-1278. https://doi.org/10.1056/NEJMoa0809335
[23]
Hauser, R.A., Lew, M.F., Hurtig, H.I., Ondo, W.G., Wojcieszek, J. and Fitzer-Attas, C.J. (2009) Long-Term Outcome of Early versus Delayed Rasagiline Treatment in Early Parkinson’s Disease. Movement Disorders, 24, 564-573. https://doi.org/10.1002/mds.22402
[24]
Hanagasi, H.A., Gurvit, H., Unsalan, P., et al. (2011) The Effects of Rasagiline on Cognitive Deficits in Parkinson’s Disease Patients without Dementia: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. Movement Disorders: Official Journal of the Movement Disorder Society, 26, 1851-1858. https://doi.org/10.1002/mds.23738
[25]
Zhang, L., Zhang, Z., Chen, Y., et al. (2013) Efficacy and Safety of Rasagiline as an Adjunct to Levodopa Treatment in Chinese Patients with Parkinson’s Disease: A Randomized, Double-Blind, Parallel-Controlled, Multi-Centre Trial. International Journal of Neuropsychopharmacology, 16, 1529-1537. https://doi.org/10.1017/S1461145713000175
[26]
Hauser, R.A., Silver, D., Choudhry, A., Eyal, E. and Isaacson, S. (2014) Randomized, Controlled Trial of Rasagiline as an Add-On to Dopamine Agonists in Parkinson’s Disease. Movement Disorders, 29, 1028-1034. https://doi.org/10.1002/mds.25877
[27]
Barone, P., Santangelo, G., Morgante, L., et al. (2015) A Randomized Clinical Trial to Evaluate the Effects of Rasagiline on Depressive Symptoms in Non-Demented Parkinson’s Disease Patients. European Journal of Neurology, 22, 1184-1191. https://doi.org/10.1111/ene.12724
[28]
Weintraub, D., Hauser, R.A., Elm, J.J., et al. (2016) Rasagiline for Mild Cognitive Impairment in Parkinson’s Disease: A Placebo-Controlled Trial. Movement Disorders: Official Journal of the Movement Disorder Society, 31, 709-714. https://doi.org/10.1002/mds.26617
[29]
Hattori, N., Takeda, A., Takeda, S., et al. (2018) Efficacy and Safety of Adjunctive Rasagiline in Japanese Parkinson’s Disease Patients with Wearing-Off Phenomena: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. Parkinsonism & Related Disorders, 53, 21-27. https://doi.org/10.1016/j.parkreldis.2018.04.025
[30]
Hattori, N., Takeda, A., Takeda, S., et al. (2019) Rasagiline Monotherapy in Early Parkinson’s Disease: A Phase 3, Randomized Study in Japan. Parkinsonism & Related Disorders, 60, 146-152. https://doi.org/10.1016/j.parkreldis.2018.08.024
[31]
Hattori, N., Takeda, A., Takeda, S., et al. (2019) Long-Term, Open-Label, Phase 3 Study of Rasagiline in Japanese Patients with Early Parkinson’s Disease. Journal of Neural Transmission, 126, 299-308. https://doi.org/10.1007/s00702-018-1964-3
[32]
Yi, H., Maruyama, W., Akao, Y., et al. (2006) N-Propargylamine Protects SH-SY5Y Cells from Apoptosis Induced by an Endogenous Neurotoxin, N-Methyl(R)Salsolinol, through Stabilization of Mitochondrial Membrane and Induction of Anti-Apoptotic Bcl-2. Journal of Neural Transmission, 113, 21-32. https://doi.org/10.1007/s00702-005-0299-z
[33]
Olanow, C.W. (2006) Rationale for Considering That Propargylamines Might Be Neuroprotective in Parkinson’s Disease. Neurology, 66, S69-S79. https://doi.org/10.1212/WNL.66.10_suppl_4.S69
[34]
Weinreb, O., Amit, T., Bar-Am, O., Chillag-Talmor, O. and Youdim, M.B.H. (2005) Novel Neuroprotective Mechanism of Action of Rasagiline Is Associated with Its Propargyl Moiety: Interaction of Bcl-2 Family Members with PKC Pathway. Annals of the New York Academy of Sciences, 1053, 348-355. https://doi.org/10.1111/j.1749-6632.2005.tb00043.x
[35]
Moustafa, A.A., Chakravarthy, S., Phillips, J.R., et al. (2016) Motor Symptoms in Parkinson’s Disease: A Unified Framework. Neuroscience & Biobehavioral Reviews, 68, 727-740. https://doi.org/10.1016/j.neubiorev.2016.07.010
[36]
Bock, M.A., Brown, E.G., Zhang, L. and Tanner, C. (2022) Association of Motor and Nonmotor Symptoms with Health-Related Quality of Life in a Large Online Cohort of People with Parkinson Disease. Neurology, 98, e2194-e2203. https://doi.org/10.1212/WNL.0000000000200113
[37]
Mantri, S., Lepore, M., Edison, B., et al. (2021) The Experience of OFF Periods in Parkinson’s Disease: Descriptions, Triggers, and Alleviating Factors. Journal of Patient-Centered Research and Reviews, 8, 232-238. https://doi.org/10.17294/2330-0698.1836
[38]
Pistacchi, M., Martinello, F., Gioulis, M. and Zambito Marsala, S. (2013) Rasagiline and Rapid Symptomatic Motor Effect in Parkinson’s Disease: Review of Literature. Neurology and Therapy, 3, 41-66. https://doi.org/10.1007/s40120-013-0014-1
Poewe, W., Antonini, A., Zijlmans, J.C., Burkhard, P.R. and Vingerhoets, F. (2010) Levodopa in the Treatment of Parkinson’s Disease: An Old Drug Still Going Strong. Clinical Interventions in Aging, 5, 229-238. https://doi.org/10.2147/CIA.S6456
[41]
Freitas, M.E., Hess, C.W. and Fox, S.H. (2017) Motor Complications of Dopaminergic Medications in Parkinson’s Disease. Seminars in Neurology, 37, 147-157. https://doi.org/10.1055/s-0037-1602423
[42]
Olanow, C.W., Agid, Y., Mizuno, Y., et al. (2004) Levodopa in the Treatment of Parkinson’s Disease: Current Controversies. Movement Disorders, 19, 997-1005. https://doi.org/10.1002/mds.20243
[43]
Todorova, A., Jenner, P. and Ray Chaudhuri, K. (2014) Non-Motor Parkinson’s: Integral to Motor Parkinson’s, yet often Neglected. Practical Neurology, 14, 310-322. https://doi.org/10.1136/practneurol-2013-000741
[44]
Parkinson, J. (2002) An Essay on the Shaking Palsy. The Journal of Neuropsychiatry and Clinical Neurosciences, 14, 223-236. https://doi.org/10.1176/jnp.14.2.223
[45]
Prenger, M.T.M., Madray, R., Van Hedger, K., Anello, M. and MacDonald, P.A. (2020) Social Symptoms of Parkinson’s Disease. Parkinson’s Disease, 2020, Article ID: 8846544. https://doi.org/10.1155/2020/8846544
[46]
Reichmann, H., Klasser, M., Apfel, R. and Fendji, D. (2015) Efficacy and Tolerability of Rasagiline in Daily Clinical Use—A Post Marketing Observational Study in Patients with Parkinson’s Disease Focusing on Non-Motor Symptoms and QoL. Basal Ganglia, 5, 101-106. https://doi.org/10.1016/j.baga.2015.09.003
[47]
Poewe, W. (2008) Non-Motor Symptoms in Parkinson’s Disease. European Journal of Neurology, 15, 14-20. https://doi.org/10.1111/j.1468-1331.2008.02056.x
[48]
Asano, H., Tian, Y.S., Hatabu, A., Takagi, T., Ueda, M. and Ikeda, K. (2023) Safety Comparisons among Monoamine Oxidase Inhibitors against Parkinson’s Disease Using FDA Adverse Event Reporting System. Scientific Reports, 13, Article No. 19272. https://doi.org/10.1038/s41598-023-44142-2
[49]
Tábi, T., Vécsei, L., Youdim, M.B., Riederer, P. and Szökő, É. (2019) Selegiline: A Molecule with Innovative Potential. Journal of Neural Transmission, 127, 831-842. https://doi.org/10.1007/s00702-019-02082-0
[50]
Müller, T., Hoffmann, J.A., Dimpfel, W. and Oehlwein, C. (2012) Switch from Selegiline to Rasagiline Is Beneficial in Patients with Parkinson’s Disease. Journal of Neural Transmission, 120, 761-765. https://doi.org/10.1007/s00702-012-0927-3
[51]
Kulisevsky, J. (2015) Emerging Role of Safinamide in Parkinson’s Disease Therapy. European Neurological Review, 9, 108-112. https://doi.org/10.17925/ENR.2014.09.02.108
